Advertisement
U.S. Markets closed
S&P Futures
5,888.25 -8.00 (-0.14%) Dow Futures
43,135.00 -42.00 (-0.10%) Nasdaq Futures
20,476.75 -42.75 (-0.21%) Russell 2000 Futures
2,250.50 -5.00 (-0.22%) Crude Oil
70.27 -0.29 (-0.41%) Gold
2,743.40 +4.50 (+0.16%)
Novo Nordisk A/S (NOVA.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Follow
At close: 09:50PM CEST
| Previous Close | 109.00 |
| Open | 109.00 |
| Bid | 108.00 x 100000 |
| Ask | 108.50 x 100000 |
| Day's Range | 107.50 - 109.00 |
| 52 Week Range | 87.20 - 140.00 |
| Volume | |
| Avg. Volume | 813 |
| Market Cap | 477.207B |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | 40.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.33 (1.22%) |
| Ex-Dividend Date | Aug 16, 2024 |
| 1y Target Est | N/A |
- GuruFocus.com
Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics
SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U. Approval
- Zacks
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.